Projected Price to Earnings: Neuphoria Therapeutics (NEUP)

Official company branding of Neuphoria Therapeutics (NEUP)

Neuphoria Therapeutics Inc. (NEUP) develops treatments for anxiety and depression with sales that remain resilient during crises. This defensive biopharmaceutical business relies on clinical trial results rather than GDP. The company's expected P/E ratio indicates a market overvaluation of the asset, where the value 0.00 describes the current level. The brand maintains an impeccable image and a high level of credibility within the scientific community.

Price to Expected Earnings Ratio: Neuphoria Therapeutics Inc. (NEUP) for 12/25/2024 - 11/18/2026

Summary analytical data breakdowns for bionomics.com.au (NEUP)

- company stock exchange capitalization indicators:
Fundamental valuation:bionomics.com.au
Signature product of Neuphoria Therapeutics Inc.

Investors face a choice between the current price and growth potential amid stringent FDA oversight. By analyzing the issuer's forward P/E, you evaluate the ratio of market capitalization to projected annual earnings, which helps identify if the asset is overbought against the backdrop of multi-year clinical trials and the complex patents of Neuphoria Therapeutics (NEUP) that protect its market niche from competitors.

Main competitors

Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Forward P/E Multiple RGC (Regencell Bioscience Ltd)|Market Cap to Projected Earnings axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Future Price to Earnings|Supernus Corp - Future Price to Earnings Multiple|Projected Price to Earnings CPRX|Denali Therapeutics Inc. (DNLI) - Market Cap to Projected Earnings|Projected Price to Earnings HRMY (Harmony Corp)|BHVN - Projected Price to Earnings Ratio|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|Future Price to Earnings Multiple TRVI|PRAX - Future Price to Earnings|Market Cap to Projected Earnings Anavex Life Sciences AVXL|CBLL: Forward P/E Multiple|Projected Price to Earnings Prothena Corporation PLC|ALEC (alector.com) - Forward P/E Multiple|Projected Price to Earnings Annexon, Inc. (ANNX)|Future Price to Earnings Omeros Corporation (OMER)|Neurogene Inc. - Price to Future Earnings Ratio|acimmune.com - Projected Price to Earnings|Forward P/E Multiple Voyager Therapeutics Inc VYGR|NMRA - Future Price to Earnings|Forward Price to Earnings Multiple Scilex Holding Company (SCLX)|Tevogen Bio Holdings (TVGN) - Future Price to Earnings|Price to Future Earnings Ratio ACOG|Future Price to Earnings Cognition Therapeutics, Inc.|Inhibikase Therapeutics, Inc. - Price to Expected Earnings Ratio|Projected Price to Earnings SAVA (Cassava)|Market Cap to Projected Earnings Assertio Therapeutics|Coya Therapeutics, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio VTGN (VistaGen Therapeutics Inc)|Ovid Therapeutics Inc - Forward P/E Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Projected Price to Earnings|CRVO (CervoMed, Inc.) - Projected Price to Earnings|Projected Price to Earnings Alterity Therapeutics Ltd|Future Price to Earnings Clene Inc.|PepGen Inc. - Price to Expected Earnings Ratio|Projected Price to Earnings JUNS (Jupiter Neurosciences Inc)|Future Price to Earnings RLMD (Relmada Therapeutics Inc)|Annovis Bio Inc - Projected Price to Earnings|Market Cap to Projected Earnings Grace Tx (GRCE)|fireflyneuro.com - Forward P/E Multiple|Klotho Neurosciences (KLTO) - Projected Price to Earnings|NeuroSense Therapeutics, Ltd. (NRSN) - Future Price to Earnings|Price to Expected Earnings Ratio RVPH (Reviva Pharmaceuticals Holdings, Inc.)|MTVA (MetaVia) - Forward P/E Multiple|NRXS: Future Price to Earnings Multiple|Forward P/E Multiple HSDT|Forward P/E Multiple Passage Bio Inc. (PASG)|minervaneurosciences.com - Projected Price to Earnings|Forward P/E Multiple Athira ATHA|Addex Therapeutics - Forward P/E Multiple|ALZN - Forward P/E Multiple|Cyclerion (CYCN) - Future Price to Earnings|Protagenic (PTIX) - Forward P/E Multiple|Future Price to Earnings Pasithea|Price to Future Earnings Ratio CRGT (Cortigent)|Future Price to Earnings Avenue Therapeutics (ATXI)|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Projected Price to Earnings|ELYM: Projected Price to Earnings|Market Cap to Projected Earnings Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Future Price to Earnings|Marinus - Future Price to Earnings Multiple|Future Price to Earnings NKGen Biotech Inc|NRBO: Future Price to Earnings Multiple|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Projected Earnings Neurotrope|Future Price to Earnings Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Projected Price to Earnings Ratio|WENA: Projected Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Therapeutics)